<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00281034</url>
  </required_header>
  <id_info>
    <org_study_id>OASIS-2005</org_study_id>
    <secondary_id>oasis-2007</secondary_id>
    <nct_id>NCT00281034</nct_id>
  </id_info>
  <brief_title>OASIS STUDY Outcome Assessment Using SF-36 v2 in Stroke Patient Study(OASIS STUDY)</brief_title>
  <official_title>Outcome Assessment Using SF-36 v2 in Stroke Patient Study(OASIS Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyorin Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyorin Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To survey the health-related quality of life using the SF-36v2 score of patients with
           chronic brain infarction in Japan

        2. Chronic brain infarction in Japan is better than EU/USA
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Period:2005-2007

      Observation Time:baseline, 8week, 24week

      matters investigated:

        1. QOL determination using SF-36 v2

        2. Age, sex, brain infarction type, stroke severity (modified Rankin scale), side of
           stroke, complication, smoking, alcohol, dizziness-vertigo-presyncope-light headedness,
           combination medicine, subjective symptoms, psychic symptoms, rehabilitation, recurrence,
           evaluation of depression (Japan-Stroke Scale (JSS)-D)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>score of SF-36</measure>
    <time_frame>0, 8 week, 24 week</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2069</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>OASIS Study Group</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Univercity, Main hospital, general Hospital,0pen
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients whose last attack occurred more than 1 month ago

          2. Outpatients (including hospitalization for rehabilitation)

          3. Japanese nationality

          4. Patients who consented to participate in this study

          5. Group I: Patients with dizziness, vertigo, presyncope, and light-headedness which are
             likely due to secondary chronic cerebral circulation impairment associated with
             sequelae of brain infarction, and patients for whom KETAS (IBUDILAST) was prescribed
             Group II: Patients without dizziness, vertigo, presyncope, and light-headedness which
             are likely due to chronic cerebral circulation impairment associated with sequelae of
             brain infarction

        Exclusion Criteria:

          1. Patients who cannot read, understand and fill in the questionnaire by themselves

          2. Patients who idle their time away

          3. Patients who are hospitalized

          4. Patients who are undergoing treatment for dizziness, vertigo, presyncope,
             light-headedness which are likely due to chronic cerebral circulation impairment
             associated with sequelae of brain infarction

          5. Patients whose dizziness, vertigo, presyncope, and light-headedness is definitely or
             likely caused by Meniere disease, vestibular neuronitis, benign paroxysmal positional
             vertigo, otitis media, or epilepsy6. Patients whom the investigator judges are not
             suitable to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yukito Shinohara, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Federation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital</name>
      <address>
        <city>Tachikawa-City</city>
        <state>Tokyo</state>
        <zip>190-8531</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2006</study_first_submitted>
  <study_first_submitted_qc>January 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2006</study_first_posted>
  <last_update_submitted>April 10, 2012</last_update_submitted>
  <last_update_submitted_qc>April 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyorin Pharmaceutical Co.,Ltd</investigator_affiliation>
    <investigator_full_name>Yukito Shinohara</investigator_full_name>
    <investigator_title>Federation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital</investigator_title>
  </responsible_party>
  <keyword>brain infarction</keyword>
  <keyword>SF-36</keyword>
  <keyword>HRQOL</keyword>
  <keyword>Japan</keyword>
  <keyword>Post-stroke syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

